ABSI Absci Corp
Which ETFs hold ABSI? Absci Corp is held by 1 fund tracked by ETFpeek.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Currently Held By
Insider Activity
last 90 days| Date | Person | Action | Plan | Shares | Value | Score |
|---|---|---|---|---|---|---|
| 3 Aug 2026 | Ransi Mudalinayake Somaratne Chief Medical Officer | BUY | Vested (RSU) | 383,000 | — | 10 |
Trade History
7 trades| Date | Fund | Direction | Shares Changed | % Δ ETF | % Δ Position |
|---|---|---|---|---|---|
| 17 Jul 2026 | ARKG | BUYAdded | +314,481 | -0.62% | 3.05% |
| 7 Jul 2026 | ARKG | SELLReduced | -74,085 | -0.17% | 0.73% |
| 6 Jul 2026 | ARKG | SELLReduced | -100,393 | +0.19% | 0.99% |
| 1 Jul 2026 | ARKG | SELLReduced | -274,636 | +0.15% | 2.61% |
| 29 Jun 2026 | ARKG | SELLReduced | -192,623 | +0.07% | 1.83% |
| 26 Jun 2026 | ARKG | SELLReduced | -259,895 | -0.34% | 2.40% |
| 25 Jun 2026 | ARKG | SELLReduced | -675,355 | +1.15% | 6.10% |
| No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal. | |||||